Қазақша
Русский
ПОДЕЛИТЬСЯ
+7 (777) 001 44 99
Social media
Tengrinews.kz — China’s National Medical Products Administration (NMPA) has for the first time approved a Class 1 innovative drug developed with the use of artificial intelligence. The drug, Mprosevir, is intended for the treatment of COVID-19, according to Global Times.
It took just 3.5 years to develop the drug — from identifying a promising compound to successfully completing clinical trials. Traditional drug development of this kind usually takes 10 to 15 years.
During the development process, scientists and AI analyzed a database of 49 billion molecular compounds to identify the most effective candidates within just a few days.
“According to the R&D team, Mprosevir has demonstrated that genuine AI-assisted drug development is currently both efficient and feasible.
Over the following two years, the team carried out a comprehensive drug optimization process centered on the molecule, including enhancing its activity, improving its drug-like properties, reducing toxicity, and advancing it from in vitro cell experiments and mouse studies through clinical trials. AI also played a key role throughout this stage,” the publication said.
In China, Class 1 refers to fully original innovative medicines that have never previously been marketed either domestically or abroad. The new drug is intended to treat mild to moderate COVID-19 in adults.
Earlier, we reported that Kazakhstan plans to use AI to forecast demand for medicines and detect fraudulent prescriptions. This was announced by Vice Minister of Healthcare Timur Muratov.